Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01235715 · ClinicalTrials.gov registry record · Phase 4
The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery
A Phase 4 study, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT01235715 is a Phase 4 study that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 200 participants.
The verdict
NCT01235715, a Phase 4 study, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
Application of "Evicel" hemostatic matrix during operation for unilateral total knee replacement surgery (TKA) will result in decreased bleeding and postoperative drain output, a reduction in transfusion requirements, and less reduction of hemoglobin.
Interventions
- DRUG Evicel fibrin sealant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01235715
The ClinicalTrials.gov registry entry for NCT01235715 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Evicel fibrin sealant is the first listed.
NCT01235715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01235715 about?
NCT01235715 is a clinical study titled "The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery". Application of "Evicel" hemostatic matrix during operation for unilateral total knee replacement surgery (TKA) will result in decreased bleeding and postoperative drain output, a reduction in transfusion requirements, and less reduction of hemoglobin.
What is the current status of trial NCT01235715?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2010-09. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01235715?
The interventions under investigation include: Evicel fibrin sealant (DRUG).
Who is sponsoring clinical trial NCT01235715?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.